Abstract:The Veterans Health Administration (VHA) is the largest provider of opioid use disorder (OUD) care in the United States. Providing access to life-saving medications for OUD (MOUD), including buprenorphine, methadone, and naltrexone is a VHA priority. Historically, MOUD receipt has varied by patient demographics and social characteristics such as age, sex, and race. However, facility-wide VHA efforts have focused on buprenorphine expansion3 and may have altered MOUD patterns.